Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : 2016 Biotech Charity Contest -- Ignore unavailable to you. Want to Upgrade?

To: BulbaMan who wrote (262)	12/3/2016 12:02:35 AM
From: BulbaMan	Read Replies (4) \| Respond to of 311

ATTENTION BIOTECHIES: I assume, despite the less than stellar performance of most Contest portfolios in 2016, there’s still interest in a 2017 Biotech Charity Contest. Please let me know if my assumption is correct. Thanks, Bulba. 12/2/16 Contest update The Price is not right! That’s what it seems, judging by the performance of biotech stocks following Trump’s selection of Dr. Tom Price, a strident opponent of Obamacare, as his secretary of health & human services. Here’s Ars Technica on Price: “[Price] opposes abortion rights and regulations on tobacco, for instance. But he also belongs to a small, fringe, ultra-conservative and conspiracy-laden group called the Association of American Physicians and Surgeons (AAPS). Among other things, this group decries evidence-based medicine, Medicare, and Medicaid, plus it has peddled discredited, dangerous notions including that vaccines cause autism.” arstechnica.com Meanwhile, at Friday’s close, the Contest median was down -25.11% YTD (vs. down -20.45% YTD a week ago). The Nasdaq Biotech Index (NBI) was down -20.07% YTD (vs. down -15.86% YTD a week ago), while the smaller-cap S&P Biotechnology Select Industry Index (SPSIBI) was down -11.98% YTD (vs. down -5.45% YTD a week ago). The Nasdaq Composite Index (NCI) was up 4.96% YTD (vs. up 7.82% YTD a week ago). JBOG’s portfolio, up 26.48% YTD, remained in first place, with DNAJOE’s portfolio, up 20.16% YTD, and STEVEL’s portfolio, up 15.77% YTD, still in second place & third place. At Friday’s close, 6 of the 58 Contest portfolios were in the green, with 23 portfolios beating the NBI and 14 beating the SPSIBI. The 223 Contest stock picks had an average YTD loss of -18.14% and a median YTD loss of -30.69%, with 54 of the 223 Contest portfolio stocks up for the year. Below is the Top Ten list. Also below are the Top 5 & Bottom 5 Stocks for the week, ranked by % Gained and % Lost. (Prices not converted to US$ in these Tables.) Portfolio adjustments: 1) CASC did 1-6 reverse split. 2) GNVC did 1-10 reverse split. 3) AEGR merger with QLTI. AEGR received 1.0256 shares of QLTI which changed its name & symbol to Novelion & NVLN. Three Contest portfolios held AEGR; BIOADD, GHMM, WATCHIT. (All corrections, especially adjustments for splits, greatly appreciated.) Have a wonderful winter weekend biotechies. Peace & good health, Bulba 12/2/16 Rank Name Profit/Loss 1 JBOG 26,482 2 DNAJOE 20,157 3 STEVEL 15,769 4 BIOPLAY 15,266 5 BMAZ 5,168 6 USUBAN 727 7 THEOX -1,461 8 CEMBP -2,810 9 GHMM -4,100 10 TOMP -6,988 Week's Top 5 Gainers Symbol 11/25/16 12/2/16 Wk.%chg. APPY 2.80 4.05 44.64% EPIX 1.88 2.34 24.70% GBIM 0.47 0.57 21.41% NVET 4.12 4.94 19.88% ICCC 5.35 6.30 17.76% Week's Worst 5 Losers Symbol 11/25/16 12/2/16 Wk.%chg. ARWR 4.67 1.44 -69.16% ARDM 5.31 2.17 -59.13% PLX 0.51 0.31 -39.22% TVIA 1.700 1.150 -32.35% BPMC 37.47 27.01 -27.92%